Research never stops

Top Story

Evotec's Academic Bridge LAB282 with Oxford University celebrating one year of impact

Hamburg, Germany, 11 December 2017: Evotec AG announced today that LAB282, the £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

- read more

Webinar " Pluripotent Stem Cells for Drug Discovery and Toxicity Assessment"

Evotec is co-presenting a complimentary Webinar on Tuesday 05 December 2017: for detailed information and the registration form, please click here

- read more

Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells

Ncardia, a leader in standardised, validated iPSC assays for safety, phenotypic screening and disease modeling, announced today that they entered into a global non-exclusive IP licensing agreement with Evotec.

- read more
loading weather report
Loading weather report...


Dec 14, 2017 - Genesis 2017

Company Presentation December

Building integrated and high-value drug discovery alliances
2017-12_Evotec_Company presentation_December